Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21965881 | 0.88 | CRBN (0.61) | CRBNDDB1 | |
| SCHEMBL26347904 | 0.81 | DDB1 (0.34) | CRBNDDB1 | |
| SCHEMBL26328773 | 0.75 | CRBN (0.51) | CRBNDDB1ADAMTS5 | |
| SCHEMBL26328771 | 0.74 | CRBN (0.50) | CRBNDDB1TAAR1ADAMTS5 | |
| SCHEMBL26328786 | 0.71 | DDB1 (0.71) | CRBNDDB1 | |
| SCHEMBL15227523 | 0.70 | CHRM3 (0.52) | CRBNDDB1TAAR1CHRM2CHRM4 | |
| SCHEMBL26364820 | 0.69 | DDB1 (0.45) | CRBNDDB1 | |
| SCHEMBL901358 | 0.68 | CHRM1 (0.71) | TAAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL19585860 | 0.67 | CRBN (1.00) | CRBNDDB1TAAR1 | |
| SCHEMBL4198068 | 0.64 | CHRM2 (0.70) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | CRBN 1/4885DDB1 319/4885TAAR1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.